

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6586

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AbbVie (epcoritamab)	All Wales Therapeutics and Toxicology     Centre
Patient/carer groups	Allied Health Professionals Federation
<ul><li>African Caribbean Leukaemia Trust</li><li>Anthony Nolan</li></ul>	Board of Community Health Councils in Wales
	British National Formulary
	,
	Care Quality Commission
Cancer Black Care	Department of Health, Social Services     Department of Health, Social Services
Cancer52	and Public Safety for Northern Ireland
Follicular Lymphoma Foundation	Healthcare Improvement Scotland
Independent Cancer Patients Voice	Medicines and Healthcare products
Kevin Kararwa Leukaemia Trust	Regulatory Agency
Leukaemia Cancer Society	National Association of Primary Care
Leukaemia Care	National Pharmacy Association
Leukaemia UK	NHS Confederation
Lymphoma Action	NHS Wales Joint Commissioning
Macmillan Cancer Support	Committee
Maggie's Centres	Scottish Medicines Consortium
Marie Curie	Welsh Government
<ul> <li>South Asian Health Foundation</li> </ul>	
Specialised Healthcare Alliance	Possible comparator companies
Tenovus Cancer Care	Abbvie (epcoritamab)
	Amarox (lenalidomide)
Healthcare professional groups	Biocon Pharma (lenalidomide)
<ul> <li>Association of Cancer Physicians</li> </ul>	Bristol Myers Squibb (lenalidomide)
British Geriatrics Society	Celltrion Healthcare (rituximab)
British Institute of Radiology	Dr Reddy's Laboratories
British Oncology Pharmacy	(bendamustine, rituximab)
Association	Grindeks Kalceks UK (lenalidomide)
British Psychosocial Oncology Society	Incyte Biosciences UK (tafasitamab)
British Society for Haematology	Mylan (lenalidomide)
British Society of Interventional	Pfizer (rituximab)
Radiology	Ranbaxy (lenalidomide)
British Transplantation Society	Roche (obinutuzumab, rituximab)
Cancer Research UK	Sandoz (lenalidomide, rituximab)

Provisional stakeholder list for the evaluation of epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6586 Issue date: September 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
NHS Blood and Transplant	Seacross Pharmaceuticals
Royal College of General Practitioners	(bendamustine)
Royal College of Nursing	Sun Pharma (lenalidomide)
Royal College of Pathologists	Teva UK (lenalidomide)
Royal College of Physicians	Thornton & Ross (lenalidomide)
Royal College of Radiologists	·
Royal Pharmaceutical Society	Relevant research groups
Royal Society of Medicine	Cochrane Haematology Group
<ul> <li>Society and College of Radiographers</li> </ul>	Genomics England
UK Clinical Pharmacy Association	Institute of Cancer Research
UK Oncology Nursing Society	Leukaemia Busters
3, 3, ,	Lymphoma Research Trust
Others	MRC Clinical Trials Unit
Department of Health and Social Care	National Institute for Health Research
NHS England	
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6586 Issue date: September 2025



### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.